The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.
Study Type
OBSERVATIONAL
Enrollment
250
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Veneto Institute of Oncology
Padova, Italy
RECRUITINGClinicopathological characterization of apocrine invasive lobular breast carcinoma
Measured by descriptive analysis of tumor size, grade, nodal status, ER, PgR, HER2, Ki-67, androgen receptor, stage, histological features and treatment received.
Time frame: Through study completion, an average of 5 years
Disease-Free Survival
Time frame: Through study completion, an average of 5 years
Overall Survival
Time frame: Through study completion, an average of 5 years
Recurrence Rate
Measured as local, regional or distant recurrence.
Time frame: Through study completion, an average of 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adjuvant or Neoadjuvant Chemotherapy